Two Sigma Advisers’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-2,346,317
| Closed | -$21.1M | – | 1438 |
|
|
2025
Q4 | $21.1M | Buy |
2,346,317
+182,900
| +8% | +$2.52M | 0.04% | 336 |
|
|
2025
Q3 | $37.4M | Buy |
2,163,417
+70,400
| +3% | +$867K | 0.07% | 213 |
|
|
2025
Q2 | $19.6M | Buy |
2,093,017
+110,700
| +6% | +$909K | 0.04% | 340 |
|
|
2025
Q1 | $14.1M | Sell |
1,982,317
-16,000
| -0.8% | -$162K | 0.03% | 433 |
|
|
2024
Q4 | $23.3M | Buy |
1,998,317
+970,700
| +94% | +$15.1M | 0.05% | 277 |
|
|
2024
Q3 | $21.1M | Buy |
1,027,617
+257,700
| +33% | +$5.94M | 0.05% | 312 |
|
|
2024
Q2 | $17.2M | Buy |
769,917
+110,600
| +17% | +$2.63M | 0.04% | 377 |
|
|
2024
Q1 | $18.1M | Buy |
659,317
+195,300
| +42% | +$5.42M | 0.04% | 368 |
|
|
2023
Q4 | $14.1M | Buy |
464,017
+210,400
| +83% | +$6.05M | 0.03% | 416 |
|
|
2023
Q3 | $8.02M | Sell |
253,617
-24,600
| -9% | -$954K | 0.02% | 552 |
|
|
2023
Q2 | $11.3M | Sell |
278,217
-257,700
| -48% | -$10.4M | 0.03% | 451 |
|
|
2023
Q1 | $20M | Sell |
535,917
-46,300
| -8% | -$1.82M | 0.05% | 332 |
|
|
2022
Q4 | $20.3M | Sell |
582,217
-1,700
| -0.3% | -$80.8K | 0.06% | 335 |
|
|
2022
Q3 | $32.7M | Sell |
583,917
-131,300
| -18% | -$8.15M | 0.09% | 220 |
|
|
2022
Q2 | $37M | Buy |
715,217
+277,200
| +63% | +$14.1M | 0.11% | 205 |
|
|
2022
Q1 | $31.8M | Buy |
438,017
+167,300
| +62% | +$14.2M | 0.08% | 229 |
|
|
2021
Q4 | $32M | Buy |
270,717
+100,800
| +59% | +$12.6M | 0.08% | 214 |
|
|
2021
Q3 | $22.8M | Sell |
169,917
-240,300
| -59% | -$36.4M | 0.06% | 285 |
|
|
2021
Q2 | $66.4M | Sell |
410,217
-269,500
| -40% | -$21M | 0.18% | 118 |
|
|
2021
Q1 | $54.6M | Buy |
679,717
+139,200
| +26% | +$9.34M | 0.15% | 142 |
|
|
2020
Q4 | $29.4M | Buy |
540,517
+83,900
| +18% | +$3.05M | 0.08% | 259 |
|
|
2020
Q3 | $9.08M | Buy |
456,617
+127,300
| +39% | +$2.65M | 0.03% | 567 |
|
|
2020
Q2 | $6.92M | Buy |
329,317
+72,400
| +28% | +$1.23M | 0.02% | 683 |
|
|
2020
Q1 | $3.14M | Buy |
256,917
+25,000
| +11% | +$337K | 0.01% | 891 |
|
|
2019
Q4 | $3.4M | Buy |
231,917
+93,500
| +68% | +$1.3M | 0.01% | 995 |
|
|
2019
Q3 | $1.85M | Buy |
138,417
+40,800
| +42% | +$651K | ﹤0.01% | 1142 |
|
|
2019
Q2 | $1.6M | Buy |
97,617
+62,100
| +175% | +$976K | ﹤0.01% | 1312 |
|
|
2019
Q1 | $607K | Buy |
35,517
+14,400
| +68% | +$215K | ﹤0.01% | 1722 |
|
|
2018
Q4 | $288K | Buy |
+21,117
| New | +$393K | ﹤0.01% | 2001 |
|
Other funds holding NTLA
AIM
VPM
VCM
RP
